Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition
In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.
You may also be interested in...
‘Legacy’ Drugs And Former US FDA Commissioner Gottlieb’s Legacy
A surprise move to unwind FDA’s efforts to end the marketing of unapproved drugs is in keeping with the overall sense of the top-down intervention in the agency’s policies at the end of the Trump Administration. It is also an unfortunate consequence of the embrace of drug pricing as part of FDA’s mission.
Sarepta, US FDA Offer Sparring Positions Over Release OF Complete Response Letters
Following Vyondys 53 rebuff, Sarepta CEO contends it would be "disrespectful" to release the complete response letter, while FDA contends that there is nothing stopping companies from publishing the letters.
Gottlieb Unleashed: Focus on Drug Pricing To Intensify As He Rejoins AEI
Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.